Skip to content
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Clinical Immunology

The Standard of Care and Treatment Approaches

At a Glance

Partial STAT1 deficiency is usually treated with multiple antibiotics selected after laboratory testing and continued for months or years. BCG should be avoided, live vaccines need specialist review, and interferon-gamma or transplant is reserved for selected difficult cases.

Treating partial STAT1 deficiency is a highly individualized process that requires a partnership between you, an immunologist, and an infectious disease specialist. Because your immune system has a specific weakness in fighting “intracellular” bacteria like mycobacteria, the cornerstone of care is long-term, specialized antibiotic therapy [1][2].

The Foundation: Multi-Drug Antibiotic Therapy

If you have an active infection, your doctors will generally prescribe combination therapy. Depending on the bacteria’s species (such as M. tuberculosis vs environmental mycobacteria), the site, and severity, they may use two, three, or more medications [1][3].

  • Susceptibility-Guided: Your treatment is not one-size-fits-all. It is guided by the laboratory results (susceptibility testing) that support selection of treatment for your specific strain of bacteria [3][4].
  • Common Medications: Regimens often include drugs from several classes, such as macrolides (e.g., clarithromycin), rifamycins (e.g., rifampin), ethambutol, and sometimes fluoroquinolones or aminoglycosides. Patients must never start, stop, or combine these regimens without their treating team. [5][4].
  • Duration: Because mycobacteria grow very slowly and can “hide” inside cells, treatment often lasts for many months or even years to ensure the infection is completely cleared [6][7].

Adjunctive Therapy: Recombinant IFN-Gamma

In some cases, your doctor may suggest adding recombinant interferon-gamma (rIFN-γ) as an injection [6].

  • The Goal: The idea is to provide extra “alarm signals” to help your immune cells wake up and fight harder [8].
  • When It Is Used: This is generally reserved as an off-label, specialist-center option for infections that are “refractory” (not getting better with antibiotics alone) [6][9].
  • Effectiveness: Its success depends heavily on your specific genetic mutation. Because your defect is in STAT1 (downstream of the receptor), additional interferon-gamma may not reliably overcome the signaling defect, and its benefit is uncertain and variant-dependent [8][6].

Why Transplant is Rarely the First Step

You may read about Hematopoietic Stem Cell Transplant (HSCT), a procedure to replace your immune system with a donor’s. For partial STAT1 deficiency, this is generally not the standard of care [1][10].

  • Risk vs. Benefit: HSCT is a high-risk procedure with significant potential for life-threatening complications, such as Graft-versus-Host Disease (GVHD) [11][10].
  • Complete vs. Partial: HSCT is typically considered for those with complete STAT1 deficiency, where the immune system is entirely unable to respond to interferon, which can be life-threatening [12][10]. In contrast, people with the partial form often manage well for many years with appropriate antibiotic therapy, though severe, refractory disease may prompt individualized transplant discussion [10].

Vaccine Safety and Precautions

Protecting your immune system also means being careful with how it is “primed.”

  • BCG Vaccine: This live bacterial vaccine is contraindicated (should not be used) for anyone with a known or suspected STAT1 deficiency, as it can cause the very infection it is meant to prevent [13][10]. Newborn siblings of patients should also delay this vaccine until they are tested [13].
  • Other Live Vaccines: Live viral vaccines (like MMR, Varicella, or intranasal flu) carry potential risks. Your immunologist must carefully evaluate your specific immune function and genotype before these are given [10][6].
  • Inactivated Vaccines: Vaccines that are not live are safe, though their effectiveness may vary based on your immune response.

Long-Term Monitoring

Because therapy is long-term, monitoring for drug side effects is essential. This often includes regular blood tests to check your liver and kidney function, as well as specialized exams to catch any issues early. Call your specialist immediately if you experience:

  • Vision Changes: Blurry or altered color vision (especially with ethambutol).
  • Hearing Loss or Ringing in the Ears (Tinnitus): Often associated with aminoglycosides.
  • Jaundice (Yellowing of skin/eyes) or Dark Urine, severe rash, palpitations, or severe diarrhea [4].
    Every change in your treatment plan should be a discussion about how to balance fighting the bacteria while protecting your overall health [2].

Disclaimer: This information is for educational purposes and does not constitute medical advice. Treatment plans must be managed by qualified healthcare professionals.

Common questions in this guide

What is the usual treatment for a mycobacterial infection in partial STAT1 deficiency?
Active infection is usually treated with two or more antibiotics chosen for the mycobacterial species, infection site, severity, and laboratory susceptibility results. Treatment often lasts many months or years and should be directed by an immunologist and infectious disease specialist.
Why do I need more than one antibiotic, and why does treatment last so long?
Mycobacteria can grow slowly and survive inside cells, so combination therapy helps target the infection and reduce the chance of treatment failure. The exact duration depends on the organism, site, response, and specialist plan; do not stop or change medicines on your own.
Can interferon-gamma treat partial STAT1 deficiency?
Recombinant interferon-gamma may be considered as an off-label treatment at a specialist center when infection does not improve with antibiotics alone. Its benefit is uncertain because partial STAT1 deficiency affects a signaling pathway needed for interferon-gamma responses, and results depend on the specific genetic variant.
Is a stem cell transplant needed for partial STAT1 deficiency?
Hematopoietic stem cell transplant is generally not the first treatment for partial STAT1 deficiency because it carries serious risks, including graft-versus-host disease. Specialists may discuss it individually when disease is severe and does not respond to appropriate treatment; it is more commonly considered in complete STAT1 deficiency.
Can someone with STAT1 deficiency receive BCG or other live vaccines?
BCG, a live bacterial vaccine, should not be given to people with known or suspected STAT1 deficiency because it can cause mycobacterial disease. Live viral vaccines require an individualized review by an immunologist, while non-live vaccines are generally safe but may not produce a full immune response.
What monitoring is needed during long-term antibiotic treatment?
Monitoring may include regular blood tests for liver and kidney function, along with vision checks for ethambutol and hearing checks when aminoglycosides are used. Contact your treatment team promptly for vision changes, hearing loss or ringing, yellow skin or eyes, dark urine, severe rash, palpitations, or severe diarrhea.
Can I stop or change my antibiotics if I feel better?
No. Do not stop, skip, combine, or change antibiotics without speaking with the treating specialist, even if symptoms improve, because incomplete or inappropriate treatment can allow the infection to persist or become harder to treat.

Get notified when new evidence is published on Mendelian susceptibility to mycobacterial diseases due to partial STAT1 deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (13)
  1. 1

    Clinical Relevance of Gain- and Loss-of-Function Germline Mutations in STAT1: A Systematic Review.

    Zhang W, Chen X, Gao G, et al.

    Frontiers in immunology 2021; (12()):654406 doi:10.3389/fimmu.2021.654406.

    PMID: 33777053
  2. 2

    Clinical recommendations for diagnosis and management of Mendelian susceptibility to mycobacterial disease in resource-limited settings.

    Cornelissen H, Glanzmann B, van Coller A, et al.

    The journal of allergy and clinical immunology. Global 2025; (4(4)):100540 doi:10.1016/j.jacig.2025.100540.

    PMID: 41048447
  3. 3

    DISSEMINATED BACILLUS-CALMETTE-GUÉRIN INFECTIONS AND PRIMARY IMMUNODEFICIENCY DISORDERS IN SINGAPORE: A SINGLE CENTER 15-YEAR RETROSPECTIVE REVIEW.

    Ong RYL, Chan SB, Chew SJ, et al.

    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020; (97()):117-125 doi:10.1016/j.ijid.2020.05.117.

    PMID: 32497805
  4. 4

    Effective anti-mycobacterial treatment for BCG disease in patients with Mendelian Susceptibility to Mycobacterial Disease (MSMD): a case series.

    Mahdaviani SA, Fallahi M, Jamee M, et al.

    Annals of clinical microbiology and antimicrobials 2022; (21(1)):8 doi:10.1186/s12941-022-00500-y.

    PMID: 35232430
  5. 5

    Diverse Presentations of Mycobacterial Disease: a Case Series of Disseminated BCGosis in an Infant and Cutaneous Mycobacterium abscessus Infection in an Adolescent in Central India with Scoping Review of the Literature.

    Choubey S, Siddiqui F, Sharda B, et al.

    Maedica 2026; (21(1)):245-252 doi:10.26574/maedica.2026.21.1.245.

    PMID: 41978868
  6. 6

    Novel STAT1 Variants in Japanese Patients with Isolated Mendelian Susceptibility to Mycobacterial Diseases.

    Ono R, Tsumura M, Shima S, et al.

    Journal of clinical immunology 2023; (43(2)):466-478 doi:10.1007/s10875-022-01396-1.

    PMID: 36336768
  7. 7

    A rare mutation causing autosomal dominant STAT1 deficiency in a South African multiplex kindred with disseminated BCG infection.

    Greybe L, Leung D, Wieselthaler N, et al.

    BMC pediatrics 2023; (23(1)):378 doi:10.1186/s12887-023-04206-8.

    PMID: 37516851
  8. 8

    Mendelian susceptibility to mycobacterial diseases: State of the puzzle.

    Errami A, Bousfiha AA

    Qatar medical journal 2023; (2023(2)):25 doi:10.5339/qmj.2023.sqac.25.

    PMID: 38025345
  9. 9

    Current Status of the Management of Mendelian Susceptibility to Mycobacterial Disease in Mainland China.

    Ying W, Liu D, Dong X, et al.

    Journal of clinical immunology 2019; (39(6)):600-610 doi:10.1007/s10875-019-00672-x.

    PMID: 31367980
  10. 10

    Genetic, Immunological, and Clinical Features of 32 Patients with Autosomal Recessive STAT1 Deficiency.

    Le Voyer T, Sakata S, Tsumura M, et al.

    Journal of immunology (Baltimore, Md. : 1950) 2021; (207(1)):133-152 doi:10.4049/jimmunol.2001451.

    PMID: 34183371
  11. 11

    Long-Term Survival After Hematopoietic Stem Cell Transplantation for Complete STAT1 Deficiency.

    Naviglio S, Soncini E, Vairo D, et al.

    Journal of clinical immunology 2017; (37(7)):701-706 doi:10.1007/s10875-017-0430-6.

    PMID: 28815344
  12. 12

    Autosomal recessive complete STAT1 deficiency caused by compound heterozygous intronic mutations.

    Sakata S, Tsumura M, Matsubayashi T, et al.

    International immunology 2020; (32(10)):663-671 doi:10.1093/intimm/dxaa043.

    PMID: 32603428
  13. 13

    Mendelian Susceptibility to Mycobacterial Disease (MSMD): Clinical, Immunological, and Genetic Features of 22 Patients from 15 Moroccan Kindreds.

    Errami A, Baghdadi JE, Ailal F, et al.

    Journal of clinical immunology 2023; (43(4)):728-740 doi:10.1007/s10875-022-01419-x.

    PMID: 36630059

This page explains treatment, vaccine precautions, and monitoring for partial STAT1 deficiency for informational purposes only and does not constitute medical advice. Your immunologist and infectious disease specialist should guide decisions about medicines, vaccines, and transplant.